Should we treat severe sepsis with activated protein C?

Suppr

超能文献

作者信息

Mackillop Andrew

机构信息

Department of Anaesthesia, Hope Hospital, Salford M6 8HD.

出版信息

Hosp Med. 2003 May;64(5):316. doi: 10.12968/hosp.2003.64.5.1771.

DOI:10.12968/hosp.2003.64.5.1771

PMID:12789748

Abstract

摘要

相似文献

Should we treat severe sepsis with activated protein C?

Hosp Med. 2003 May;64(5):316. doi: 10.12968/hosp.2003.64.5.1771.

The development of drotrecogin alfa (activated) for the treatment of severe sepsis.

Int J Artif Organs. 2004 May;27(5):360-70. doi: 10.1177/039139880402700504.

Should we be using activated protein C to treat severe sepsis?

Br J Hosp Med (Lond). 2009 Aug;70(8):484. doi: 10.12968/hmed.2009.70.8.43548.

Risks and benefits of activated protein C treatment for severe sepsis.

N Engl J Med. 2002 Sep 26;347(13):1027-30. doi: 10.1056/NEJMsb020574.

Assessing the use of activated protein C in the treatment of severe sepsis.

N Engl J Med. 2002 Sep 26;347(13):1030-4. doi: 10.1056/NEJMsb021512.

How to ENHANCE our knowledge of activated protein C during pediatric sepsis trials: pediatric versus adult trials.

Pediatr Crit Care Med. 2006 May;7(3):277-8. doi: 10.1097/01.PCC.0000219048.44785.F6.

Activated protein C (Xigris): a drug in trouble.

Acta Anaesthesiol Scand. 2007 Feb;51(2):261-2. doi: 10.1111/j.1399-6576.2006.01215.x.

Treating severe sepsis with drotrecogin alfa (activated).

Hosp Med. 2003 Mar;64(3):168-72. doi: 10.12968/hosp.2003.64.3.1800.

Combating mortality from severe sepsis.

Hosp Med. 2004 Oct;65(10):580-1. doi: 10.12968/hosp.2004.65.10.16605.

[Treatment of severe sepsis and multiple organ failure with activated protein C].

Ugeskr Laeger. 2004 Mar 8;166(11):995.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Should we treat severe sepsis with activated protein C?

Hosp Med. 2003 May;64(5):316. doi: 10.12968/hosp.2003.64.5.1771.

The development of drotrecogin alfa (activated) for the treatment of severe sepsis.

Int J Artif Organs. 2004 May;27(5):360-70. doi: 10.1177/039139880402700504.

Should we be using activated protein C to treat severe sepsis?

Br J Hosp Med (Lond). 2009 Aug;70(8):484. doi: 10.12968/hmed.2009.70.8.43548.

Risks and benefits of activated protein C treatment for severe sepsis.

N Engl J Med. 2002 Sep 26;347(13):1027-30. doi: 10.1056/NEJMsb020574.

Assessing the use of activated protein C in the treatment of severe sepsis.

N Engl J Med. 2002 Sep 26;347(13):1030-4. doi: 10.1056/NEJMsb021512.

How to ENHANCE our knowledge of activated protein C during pediatric sepsis trials: pediatric versus adult trials.

Pediatr Crit Care Med. 2006 May;7(3):277-8. doi: 10.1097/01.PCC.0000219048.44785.F6.

Activated protein C (Xigris): a drug in trouble.

Acta Anaesthesiol Scand. 2007 Feb;51(2):261-2. doi: 10.1111/j.1399-6576.2006.01215.x.

Treating severe sepsis with drotrecogin alfa (activated).

Hosp Med. 2003 Mar;64(3):168-72. doi: 10.12968/hosp.2003.64.3.1800.

Combating mortality from severe sepsis.

Hosp Med. 2004 Oct;65(10):580-1. doi: 10.12968/hosp.2004.65.10.16605.

[Treatment of severe sepsis and multiple organ failure with activated protein C].

Ugeskr Laeger. 2004 Mar 8;166(11):995.